

# George Perry

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5528737/publications.pdf](https://exaly.com/author-pdf/5528737/publications.pdf)

Version: 2024-02-01

779  
papers

70,903  
citations

489

128  
h-index

1080

232  
g-index

1061  
all docs

1061  
docs citations

1061  
times ranked

61259  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fabrication and Characterization of Quad-Component Bioinspired Hydrogels to Model Elevated Fibrin Levels in Central Nervous Tissue Scaffolds. <i>Gels</i> , 2024, 10, 203.	4.7	0
2	Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues. <i>ACS Chemical Neuroscience</i> , 2024, 15, 1469-1483.	3.7	0
3	Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3892.	4.2	4
4	Central role of brain regulatory T cells in the inflammatory cascade in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2024, 121, .	7.6	0
5	Sensory Dysfunction, Microbial Infections, and Host Responses in Alzheimer's Disease. <i>Journal of Infectious Diseases</i> , 2024, 230, S150-S164.	3.9	0
6	Natural Product Co-Metabolism and the Microbiota-Gut-Brain Axis in Age-Related Diseases. <i>Life</i> , 2023, 13, 41.	2.5	2
7	FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls. <i>Diagnostics</i> , 2023, 13, 2254.	2.8	4
8	The Teflon hypothesis. <i>Brain Communications</i> , 2023, 5, .	3.4	1
9	Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12486.	4.2	5
10	Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer's Disease. <i>Antioxidants</i> , 2023, 12, 1628.	5.2	18
11	Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. <i>Alzheimer's and Dementia</i> , 2022, 18, 1248-1259.	0.7	13
12	Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. <i>Reviews in the Neurosciences</i> , 2022, 33, 365-381.	3.2	6
13	Conformation- and phosphorylation-dependent electron tunnelling across self-assembled monolayers of tau peptides. <i>Journal of Colloid and Interface Science</i> , 2022, 606, 2038-2050.	9.6	2
14	Alzheimer's Disease Pharmacology. , 2022, , 34-63.		2
15	Optogenetics: implications for Alzheimer's disease research and therapy. <i>Molecular Brain</i> , 2022, 15, 20.	3.0	16
16	Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 529-543.	2.7	5
17	Hypoxic Preconditioning Averts Sporadic Alzheimer's Disease-Like Phenotype in Rats: A Focus on Mitochondria. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 739-757.	5.5	8
18	Making the Case for Accelerated Withdrawal of Aducanumab. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1003-1007.	2.7	21

#	ARTICLE	IF	CITATIONS
19	Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 305-315.	2.7	14
20	Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia. <i>American Journal of Pathology</i> , 2022, 192, 1340-1346.	4.1	16
21	Therapeutic Antiaging Strategies. <i>Biomedicines</i> , 2022, 10, 2515.	3.3	12
22	Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 591-610.	5.5	98
23	Reactive Oxygen Species and Their Impact in Neurodegenerative Diseases: Literature Landscape Analysis. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 402-420.	5.5	76
24	A Multilevel View of the Development of Alzheimer's Disease. <i>Neuroscience</i> , 2021, 457, 283-293.	2.4	46
25	MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness. <i>American Journal of Medicine</i> , 2021, 134, 153-155.	1.4	31
26	Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 150-165.	9.8	74
27	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. , 2021, , 427-455.		0
28	Alzheimer's and Consciousness: How Much Subjectivity Is Objective?. <i>Neuroscience Insights</i> , 2021, 16, 263310552110338.	1.6	1
29	Strawberry ( <i>Fragaria ananassa</i> Duch.) Alba extract attenuates DNA damage in lymphocytes of patients with Alzheimer's disease. <i>Journal of Food Biochemistry</i> , 2021, 45, e13637.	2.9	2
30	Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1517-1531.	2.7	9
31	Challenges and Strategies of Successful Mentoring: The Perspective of LEADS Scholars and Mentors from Minority Serving Institutions. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6155.	2.7	9
32	Biogenic metallic elements in the human brain?. <i>Science Advances</i> , 2021, 7, .	10.9	53
33	Community Engagement Practices at Research Centers in U.S. Minority Institutions: Priority Populations and Innovative Approaches to Advancing Health Disparities Research. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6675.	2.7	7
34	Oxidative Stress Signaling in Blast TBI-Induced Tau Phosphorylation. <i>Antioxidants</i> , 2021, 10, 955.	5.2	11
35	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021, 69, 101346.	11.2	85
36	Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2021, 156, 105403.	4.5	50

#	ARTICLE	IF	CITATIONS
37	The Amyloid- $\beta^2$ Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	8.2	643
38	American Dementia: Brain Health in an Unhealthy Society by Daniel R. George and Peter J. Whitehouse, Johns Hopkins Press, 2021, 390 pp.. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 935-935.	2.7	0
39	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. , 2021, , 411-426.		0
40	Mitochondrial Fusion Suppresses Tau Pathology-Induced Neurodegeneration and Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1057-1069.	2.7	6
41	Gut's microbiota's microglia's brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 177.	6.4	16
42	SWADESH: A Comprehensive Platform for Multimodal Data and Analytics for Advanced Research in Alzheimer's Disease and Other Brain Disorders. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-5.	2.7	4
43	Editorial: Oxidative Stress Revisited's Major Role in Vascular Diseases, Volume II. <i>Frontiers in Physiology</i> , 2021, 12, 826129.	2.8	0
44	Functional study in the young rTg4510 mouse model of tauopathy. <i>Alzheimer's and Dementia</i> , 2021, 17, e058539.	0.7	0
45	Pathogenesis of Alzheimer's Disease. , 2021, , 1-20.		0
46	TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165580.	3.8	19
47	Status and future directions of clinical trials in Alzheimer's disease. <i>International Review of Neurobiology</i> , 2020, 154, 3-50.	1.8	32
48	Toll-like receptors in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2020, 348, 577362.	2.4	38
49	Association of plasma YKL-40 with brain amyloid- $\beta^2$ levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32.	3.2	26
50	A brief guide to the science and art of writing manuscripts in biomedicine. <i>Journal of Translational Medicine</i> , 2020, 18, 425.	4.5	24
51	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. <i>EBioMedicine</i> , 2020, 57, 102834.	6.0	63
52	The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2624.	2.5	12
53	Ethanol-Fixed, Paraffin-Embedded Tissue Imaging: Implications for Alzheimer's Disease Research. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 2416-2420.	3.1	6
54	RNA and Oxidative Stress in Alzheimer's Disease: Focus on microRNAs. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-16.	4.1	71

#	ARTICLE	IF	CITATIONS
55	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042621.	0.7	1
56	Î±-Synuclein and tau, two targets for dementia. <i>Studies in Natural Products Chemistry</i> , 2020, 67, 1-25.	0.0	6
57	Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. <i>Molecular Neurodegeneration</i> , 2020, 15, 30.	11.8	648
58	The Role of the Microbiota-Gut-Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases. <i>Microorganisms</i> , 2020, 8, 784.	3.6	40
59	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 553-569.	2.7	15
60	Role of antioxidants and a nutrient rich diet in Alzheimer's disease. <i>Open Biology</i> , 2020, 10, 200084.	3.7	44
61	National Dementia BioBank: A Strategy for the Diagnosis and Study of Neurodegenerative Diseases in Mexico. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 853-862.	2.7	4
62	Alzheimer's Disease Patients in the Crosshairs of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1-1.	2.7	17
63	Polyphenols in Alzheimer's Disease and in the Gut-Brain Axis. <i>Microorganisms</i> , 2020, 8, 199.	3.6	74
64	The Microbiota-Gut-Brain Axis-Heart Shunt Part II: Prosaic Foods and the Brain-Heart Connection in Alzheimer Disease. <i>Microorganisms</i> , 2020, 8, 493.	3.6	20
65	Unraveling the Role of Mitochondria in Alzheimer's Disease. , 2020, , 407-430.		1
66	Hippocampal Unicellular Recordings and Hippocampal-dependent Innate Behaviors in an Adolescent Mouse Model of Alzheimer's disease. <i>Bio-protocol</i> , 2020, 10, e3529.	0.4	2
67	INVITED ARTICLE FROM THE 2020 TEXAS ACADEMY OF SCIENCE TEXAS DISTINGUISHED SCIENTIST. <i>Texas Journal of Science</i> , 2020, 72, .	0.2	0
68	Implication of ferroptosis iron-dependent programmed cell death mechanism in neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e043978.	0.7	6
69	Differences in structure and function between human and murine tau. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2024-2030.	3.8	22
70	Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. <i>Neurotherapeutics</i> , 2019, 16, 666-674.	4.7	210
71	Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 631-645.	2.7	12
72	Editorial: Oxidative Stress Revisited-Major Role in Vascular Diseases. <i>Frontiers in Physiology</i> , 2019, 10, 788.	2.8	2

#	ARTICLE	IF	CITATIONS
73	Neuropsychiatric Disturbances and Diabetes Mellitus: The Role of Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-2.	4.1	14
74	Neuropathology in Consecutive Forensic Consultation Cases with a History of Remote Traumatic Brain Injury. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 683-691.	2.7	3
75	Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma. <i>Brain</i> , 2019, 142, 3672-3693.	8.0	60
76	TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration. <i>Molecular and Cellular Neurosciences</i> , 2019, 100, 103396.	2.2	69
77	Gait Disorders in Alzheimer's Disease and Other Dementias: There is Something in the Way You Walk. <i>Journal of Alzheimer's Disease</i> , 2019, 71, S1-S4.	2.7	10
78	Current research in biotechnology: Exploring the biotech forefront. <i>Current Research in Biotechnology</i> , 2019, 1, 34-40.	3.8	17
79	Single-channel permeability and glycerol affinity of human aquaglyceroporin AQP3. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2019, 1861, 768-775.	2.7	20
80	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 615-629.	2.7	49
81	Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1077-1087.	2.7	9
82	The Research Centers in Minority Institutions (RCMI) Translational Research Network: Building and Sustaining Capacity for Multi-Site Basic Biomedical, Clinical and Behavioral Research. <i>Ethnicity and Disease</i> , 2019, 29, 135-144.	2.2	26
83	Rapid method towards proteomic analysis of dried blood spots by MALDI mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2019, 12, 30-36.	1.9	4
84	The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation. <i>Biomedicines</i> , 2019, 7, 24.	3.3	26
85	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1-24.	2.7	79
86	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 15.	6.4	25
87	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.1	203
88	No Evidence of Increased Chronic Traumatic Encephalopathy Pathology or Neurodegenerative Proteinopathy in Former Military Service Members: A Preliminary Study. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1277-1289.	2.7	13
89	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. <i>Laboratory Investigation</i> , 2019, 99, 958-970.	3.9	90
90	P4513: ACTIVATION OF FERROPTOSIS, AN IRON-DEPENDENT FORM OF NON-APOPTOTIC DEATH IN NEURONS. <i>Alzheimer's and Dementia</i> , 2019, 15, P1510.	0.7	0

#	ARTICLE	IF	CITATIONS
91	Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 447-467.	2.7	75
92	Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2048-2059.	3.8	54
93	Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2040-2047.	3.8	17
94	The sterol regulatory element-binding protein 2 is dysregulated by tau alterations in Alzheimer disease. <i>Brain Pathology</i> , 2019, 29, 530-543.	4.2	11
95	MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. <i>Seminars in Cancer Biology</i> , 2019, 56, 185-195.	9.8	111
96	Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders. <i>Molecular Neurobiology</i> , 2019, 56, 307-318.	4.1	10
97	Pathomechanisms of TDP43 in neurodegeneration. <i>Journal of Neurochemistry</i> , 2018, 146, 7-20.	4.0	171
98	Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. <i>Nanoscale</i> , 2018, 10, 11782-11796.	5.8	90
99	Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer's model. <i>Journal of Biological Chemistry</i> , 2018, 293, 8462-8472.	3.5	63
100	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	7.2	79
101	Expression of growth hormone gene in the baboon eye. <i>Experimental Eye Research</i> , 2018, 169, 157-169.	2.7	8
102	Iron facts about dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 446-447.	6.0	3
103	Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta-analysis in human pathological specimens. <i>Free Radical Biology and Medicine</i> , 2018, 115, 351-360.	4.5	83
104	Characterization of Proteins Present in Isolated Senile Plaques from Alzheimer's Diseased Brains by MALDI-TOF MS with MS/MS. <i>ACS Chemical Neuroscience</i> , 2018, 9, 708-714.	3.7	12
105	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 157-165.	2.7	32
106	Thermodynamics of Amyloid- $\beta$ Fibril Elongation: Atomistic Details of the Transition State. <i>ACS Chemical Neuroscience</i> , 2018, 9, 783-789.	3.7	35
107	Incubation with Cu(II) and Zn(II) salts enhances MALDI-TOF mass spectra of amyloid- $\beta$ and $\alpha$ -synuclein toward in vivo analysis. <i>Journal of Mass Spectrometry</i> , 2018, 53, 162-171.	1.8	4
108	Preface: Alzheimer's Disease: New Beginnings. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S1-S1.	2.7	0

#	ARTICLE	IF	CITATIONS
109	Vascular Oxidative Stress: Impact and Therapeutic Approaches. <i>Frontiers in Physiology</i> , 2018, 9, 1668.	2.8	171
110	Birth of JAD: 20 Years Later. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 901-901.	2.7	1
111	Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid- $\beta^2$ Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 467-476.	2.7	19
112	Genetic Risk of Alzheimer's Disease: Three Wishes Now That the Genie is Out of the Bottle. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 421-423.	2.7	3
113	An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 453-460.	2.7	12
114	From Oxidative Stress to Ageing via Lifestyle, Nutraceuticals, Polypharmacy, and Neuropsychological Factors. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-2.	4.1	6
115	Drug-Abuse Nanotechnology: Opportunities and Challenges. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2288-2298.	3.7	9
116	Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1269-1277.	2.7	5
117	Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers. <i>Current Alzheimer Research</i> , 2018, 15, 164-181.	1.5	53
118	Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. <i>Cell Metabolism</i> , 2018, 28, 400-414.e8.	15.8	42
119	Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex. <i>Molecular Neurodegeneration</i> , 2018, 13, 5.	11.8	85
120	Towards an Integrative Understanding of tRNA Aminoacylation: Diet-Host-Gut Microbiome Interactions in Neurodegeneration. <i>Nutrients</i> , 2018, 10, 410.	4.2	26
121	Gibbs Free-Energy Gradient along the Path of Glucose Transport through Human Glucose Transporter 3. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2815-2823.	3.7	13
122	Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements. <i>Cancer Biomarkers</i> , 2018, 22, 179-198.	1.7	2
123	Anthocyanins: Multi-Target Agents for Prevention and Therapy of Chronic Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6321-6346.	1.9	34
124	Nutritional supplements and dementia. <i>Clinical Nutrition</i> , 2017, 36, 613-614.	5.1	0
125	Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1232-1241.	3.7	36
126	Elongation affinity, activation barrier, and stability of A $\beta$ 242 oligomers/fibrils in physiological saline. <i>Biochemical and Biophysical Research Communications</i> , 2017, 487, 444-449.	2.2	13



#	ARTICLE	IF	CITATIONS
127	Affinity and path of binding xylopyranose unto E.Âcoli xylose permease. Biochemical and Biophysical Research Communications, 2017, 494, 202-206.	2.2	10
128	Dementia Pugilistica Revisited. Journal of Alzheimer's Disease, 2017, 60, 1209-1221.	2.7	34
129	Inhibition of mitochondrial fragmentation protects against Alzheimerâ€™s disease in rodent model. Human Molecular Genetics, 2017, 26, 4118-4131.	3.0	131
130	Consequences of RNA oxidation on protein synthesis rate and fidelity: implications for the pathophysiology of neuropsychiatric disorders. Biochemical Society Transactions, 2017, 45, 1053-1066.	3.4	44
131	Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to Î² sheet in tau protein linked to Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 945-953.	5.7	72
132	Advances in Alzheimerâ€™s Diagnosis and Therapy: The Implications of Nanotechnology. Trends in Biotechnology, 2017, 35, 937-953.	9.5	125
133	The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features. Journal of Alzheimer's Disease, 2017, 61, 17-28.	2.7	49
134	Antioxidants in theÂPrevention and Treatment of Alzheimerâ€™s Disease. , 2017, , 523-553.		3
135	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 43-67.	0.8	7
136	Alzheimer's and Parkinson's Disease Novel Therapeutic Target. International Journal of Knowledge Discovery in Bioinformatics, 2017, 7, 68-82.	0.8	2
137	BARHL1 Is Downregulated in Alzheimerâ€™s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 2017, 8, 245.	2.4	57
138	Slower Dynamics and Aged Mitochondria in Sporadic Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	4.1	99
139	Metals and Mitochondria in Neurodegeneration. , 2017, , 283-311.		0
140	TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 1027-1033.	2.7	9
141	Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget, 2016, 7, 38999-39016.	2.1	60
142	Overview of Alzheimerâ€™s Disease and Some Therapeutic Approaches Targeting A<i>Î²</i> by Using Several Synthetic and Herbal Compounds. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-22.	4.1	131
143	Promise from the Sea. Marine Drugs, 2016, 14, 178.	4.6	2
144	Loss of JAM-C leads to impaired esophageal innervations and megaesophagus in mice. Ecological Management and Restoration, 2016, 29, 864-871.	0.5	4

#	ARTICLE	IF	CITATIONS
145	1,3-propanediol binds deep inside the channel to inhibit water permeation through aquaporins. <i>Protein Science</i> , 2016, 25, 433-441.	7.8	7
146	Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 73-75.	2.7	6
147	Fibrillar Amyloid- $\beta^2$ Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3 $\times$ Tg-AD Transgenic Mouse. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 243-269.	2.7	20
148	Estrogen receptor- $\alpha$ is localized to neurofibrillary tangles in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 20352.	3.4	47
149	High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 24873.	3.4	114
150	Meta-analysis of Telomere Length in Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1069-1073.	3.7	178
151	Mitochondrial traffic jams in Alzheimer's disease - pinpointing the roadblocks. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1909-1917.	3.8	76
152	Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 749-762.	2.7	36
153	Microbes and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 979-984.	2.7	445
154	Beta-amyloid 1 $\times$ 42 monomers, but not oligomers, produce $\alpha$ -like conformation of Tau protein. <i>Aging Cell</i> , 2016, 15, 914-923.	6.8	28
155	Nucleic acid oxidative damage in Alzheimer's disease explained by the hepcidin-ferroportin neuronal iron overload hypothesis?. <i>Journal of Trace Elements in Medicine and Biology</i> , 2016, 38, 1-9.	3.2	37
156	Morphometric analysis of cryofixed muscular tissue for intraoperative consultation. <i>Microscopy Research and Technique</i> , 2016, 79, 155-161.	2.3	0
157	Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 7053-7060.	2.9	12
158	Scientific Information Security in Information Science and Academic Publishing. <i>Artificial Organs</i> , 2016, 40, 425-430.	2.0	1
159	Cerebrovascular and mitochondrial abnormalities in Alzheimer's disease: a brief overview. <i>Journal of Neural Transmission</i> , 2016, 123, 107-111.	2.9	14
160	Prefrontal white matter pathology in air pollution exposed Mexico City young urbanites and their potential impact on neurovascular unit dysfunction and the development of Alzheimer's disease. <i>Environmental Research</i> , 2016, 146, 404-417.	7.7	142
161	PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease. <i>Human Molecular Genetics</i> , 2016, 25, 792-806.	3.0	142
162	Telomere length in Parkinson's disease: A meta-analysis. <i>Experimental Gerontology</i> , 2016, 75, 53-55.	2.9	53

#	ARTICLE	IF	CITATIONS
163	Laser-Induced In-Source Decay Applied to the Determination of Amyloid-Beta in Alzheimer's Brains. ACS Chemical Neuroscience, 2016, 7, 261-268.	3.7	23
164	Current needs for human and medical genomics research infrastructure in low and middle income countries: Table A1. Journal of Medical Genetics, 2016, 53, 438-440.	3.6	20
165	Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer's disease. Molecular Psychiatry, 2016, 21, 1263-1271.	8.2	37
166	Oxidative Stress and Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 189-198.	0.0	8
167	Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease. Current Alzheimer Research, 2016, 14, 40-46.	1.5	17
168	Oxidative Stress Induces Senescence in Cultured RPE Cells. The Open Neurology Journal, 2016, 10, 83-87.	0.4	24
169	Molecular Mapping Alzheimer's Disease: MALDI Imaging of Formalin-fixed, Paraffin-embedded Human Hippocampal Tissue. The Open Neurology Journal, 2016, 10, 88-98.	0.4	9
170	The Role of the Iron Stain in Assessing Intracranial Hemorrhage. The Open Neurology Journal, 2016, 10, 136-142.	0.4	7
171	Functional and Genomic Features of Human Genes Mutated in Neuropsychiatric Disorders. The Open Neurology Journal, 2016, 10, 143-148.	0.4	5
172	P3-029: Oxidative damage is correlated with mitochondrial autophagy. Alzheimer's and Dementia, 2015, 11, P630-P630.	0.7	0
173	Chronic Effects of Mild Neurotrauma. Journal of Neuropathology and Experimental Neurology, 2015, 74, 493-499.	1.8	35
174	A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks. Journal of Alzheimer's Disease, 2015, 44, 549-560.	2.7	51
175	P2-152: Molecular mapping of Alzheimer's disease: Imaging mass spectrometry. Alzheimer's and Dementia, 2015, 11, P545-P545.	0.7	0
176	Geometric complexity identifies platelet activation in familial hypercholesterolemic patients. Microscopy Research and Technique, 2015, 78, 519-522.	2.3	3
177	Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Translational Neurodegeneration, 2015, 4, 14.	8.2	53
178	Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in Sjogren's syndrome patients. Microscopy Research and Technique, 2015, 78, 1069-1074.	2.3	10
179	Geometric complexity is increased in in vitro activated platelets. Microscopy Research and Technique, 2015, 78, 485-488.	2.3	2
180	Simultaneous Onset of Alzheimer's Disease in a Husband and Wife in Their Mid-Fifties: What Do We Really Know About Environmental Factors?. The Open Neurology Journal, 2015, 9, 1-3.	0.4	1

#	ARTICLE	IF	CITATIONS
181	Two Hundred Treasured Issues!. Journal of Alzheimer's Disease, 2015, 44, 725-725.	2.7	0
182	Miro1 deficiency in amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience, 2015, 7, 100.	3.5	56
183	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience, 2015, 9, 145.	2.9	7
184	Ra Mena: 19532014. Journal of Alzheimer's Disease, 2015, 45, 325-327.	2.7	1
185	Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environmental Research, 2015, 140, 579-592.	7.7	81
186	Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cellular Immunology, 2015, 295, 83-91.	3.0	7
187	Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1 <i>H</i> -indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. ACS Chemical Neuroscience, 2015, 6, 1393-1399.	3.7	53
188	From Neurodegeneration to Brain Health: AnIntegrated Approach. Journal of Alzheimer's Disease, 2015, 46, 271-283.	2.7	7
189	Posttranslational modifications of -tubulin in alzheimer disease. Translational Neurodegeneration, 2015, 4, 9.	8.2	94
190	Autophagy in Alzheimers disease: A Cleaning Service Out-of-order?. Current Topics in Neurotoxicity, 2015, , 123-142.	0.0	1
191	Alterations of the X Chromosome in Lymphocytes of Alzheimers Disease Patients. Current Alzheimer Research, 2015, 12, 990-996.	1.5	7
192	Low Dose Pioglitazone Attenuates Oxidative Damage in Early Alzheimer's Disease by Binding mitoNEET. International Journal of Knowledge Discovery in Bioinformatics, 2015, 5, 24-45.	0.8	5
193	Oxidative Damage is Correlated with Mitochondrial Autophagy. FASEB Journal, 2015, 29, 613.1.	0.5	0
194	Differential Network Analyses of Alzheimers Disease Identify Early Events in Alzheimers Disease Pathology. International Journal of Alzheimer's Disease, 2014, 2014, 1-18.	2.5	12
195	Ethics Review as a Catalyst for Progress. Journal of Alzheimer's Disease, 2014, 40, 233-235.	2.7	3
196	Precision medicine using individualized biosimulations of drug dosing: Alzheimer's disease. , 2014, , .		6
197	Global warming and neurodegenerative disorders: speculations on their linkage. BiolImpacts, 2014, 4, 167-170.	1.6	11
198	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	4.0	121

#	ARTICLE	IF	CITATIONS
199	The complexities of the pathologyâ€™pathogenesis relationship in Alzheimer disease. <i>Biochemical Pharmacology</i> , 2014, 88, 671-676.	4.6	78
200	Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1240-1247.	3.8	1,020
201	Looking At Alzheimerâ€™s Disease From A Different Angle. <i>Future Neurology</i> , 2014, 9, 19-22.	0.5	0
202	Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 615-620.	4.6	79
203	Parallels Between Major Depressive Disorder and Alzheimerâ€™s Disease: Role of Oxidative Stress and Genetic Vulnerability. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 925-949.	3.3	86
204	Neuronal failure in Alzheimerâ€™s disease: a view through the oxidative stress looking-glass. <i>Neuroscience Bulletin</i> , 2014, 30, 243-252.	3.6	98
205	Pathogenesis of Alzheimerâ€™s Disease. , 2014, , 2327-2337.		1
206	Plaques and tangles: Birthmarks of the aging soul. <i>Biochemical Pharmacology</i> , 2014, 88, 423-425.	4.6	4
207	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. <i>Current Alzheimer Research</i> , 2014, 11, 165-174.	1.5	57
208	Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer&#39;s Disease. <i>Current Alzheimer Research</i> , 2014, 11, 928-940.	1.5	81
209	Alzheimer Disease Pathology in Middle Age Reveals a Spatial-Temporal Disconnect Between Amyloid- $\beta$ and Phosphorylated Tau. <i>The Open Neurology Journal</i> , 2014, 8, 22-26.	0.4	11
210	Methemoglobinemiaâ€™A biomarker and a link to ferric iron accumulation in Alzheimerâ€™s disease. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2014, 05, 12-18.	0.7	5
211	Neuropsychiatric genetics in developing countries: Current challenges. <i>World Journal of Psychiatry</i> , 2014, 4, 69.	2.8	27
212	Modification of Amyloid- $\beta$ 1-42 Fibril Structure by Methionine-35 Oxidation. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 9-18.	2.7	23
213	Antimicrobial peptide $\beta$ -defensin-1 expression is upregulated in Alzheimerâ€™s brain. <i>Journal of Neuroinflammation</i> , 2013, 10, 127.	7.4	43
214	The Structures of the E22 $\beta$ Mutant-Type Amyloid- $\beta$ Alloforms and the Impact of E22 $\beta$ Mutation on the Structures of the Wild-Type Amyloid- $\beta$ Alloforms. <i>ACS Chemical Neuroscience</i> , 2013, 4, 310-320.	3.7	39
215	Mitochondrial DNA Oxidative Damage and Repair in Aging and Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 2444-2457.	5.5	144
216	Amyloid $\beta$ peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system. <i>Neurobiology of Aging</i> , 2013, 34, 2071-2076.	3.2	23

#	ARTICLE	IF	CITATIONS
217	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 108-116.	1.5	5
218	Proteolytic Cleavage of Polymeric Tau Protein by Caspase-3: Implications for Alzheimer Disease. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2013, 72, 1145-1161.	1.8	44
219	Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-6.	4.1	113
220	Nutrients and Food Constituents in Cognitive Decline and Neurodegenerative Disease. , 2013, , 373-390.		0
221	A Low-Molecular-Weight Ferroxidase Is Increased in the CSF of sCJD Cases: CSF Ferroxidase and Transferrin as Diagnostic Biomarkers for sCJD. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 1662-1675.	5.5	22
222	Foreword (The Largest Unmet Market: Chronic Diseases of Aging). <i>Mini-Reviews in Medicinal Chemistry</i> , 2013, 13, 1-1.	2.6	6
223	Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-13.	4.1	100
224	Are Alzheimer's Disease and Aging Evolutionary?. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 637-637.	2.7	1
225	Larry Sparks: Innovator and Iconoclast. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 1-1.	2.7	0
226	Apolipoprotein E4 Prevents Growth of Malaria at the Intraerythrocyte Stage: Implications For Differences in Racial Susceptibility to Alzheimer's Disease. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 70-78.	0.8	27
227	Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 406-419.	1.5	111
228	Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency. <i>Current Alzheimer Research</i> , 2013, 10, 987-1004.	1.5	37
229	Fractal Analysis of Epithelial-Connective Tissue Interface in Basal Cell Carcinoma of the Skin. <i>Current Bioinformatics</i> , 2013, 8, 357-361.	1.3	6
230	Tackling the Elusive Challenges Relevant to Conquering the 100-Plus Year Old Problem of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 108-116.	1.5	5
231	Alzheimer's Disease and Vascular Deficiency: Lessons from Imaging Studies and Down Syndrome. <i>Current Gerontology and Geriatrics Research</i> , 2012, 2012, 1-5.	1.8	5
232	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. <i>Human Molecular Genetics</i> , 2012, 21, 1931-1944.	3.0	365
233	Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest. <i>Current Alzheimer Research</i> , 2012, 9, 1168-1173.	1.5	0
234	Editorial [Special Issue in Honor of the 70th Birthday of Dr. Atta-ur-Rahman, FRS]. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, i-i.	2.6	0

#	ARTICLE	IF	CITATIONS
235	Cellular prion protein is essential for oligomeric amyloid- $\beta$ -induced neuronal cell death. <i>Human Molecular Genetics</i> , 2012, 21, 1138-1144.	3.0	106
236	Molecular Neuropathogenesis of Alzheimer's Disease: An Interaction Model Stressing the Central Role of Oxidative Stress. <i>Future Neurology</i> , 2012, 7, 287-305.	0.5	13
237	Iron Chelation and Nanoparticle Target Delivery in the Development of New Multifunctional disease-modifying Drugs for Alzheimer's Disease. <i>Therapeutic Delivery</i> , 2012, 3, 571-574.	2.5	2
238	Editorial (A New Era for Medicinal Chemistry). <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1-1.	2.6	9
239	Neuroinflammation, Hyperphosphorylated Tau, Diffuse Amyloid Plaques, and Down-Regulation of the Cellular Prion Protein in Air Pollution Exposed Children and Young Adults. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 93-107.	2.7	238
240	The Earliest Stage of Cognitive Impairment in Transition From Normal Aging to Alzheimer Disease Is Marked by Prominent RNA Oxidation in Vulnerable Neurons. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2012, 71, 233-241.	1.8	105
241	Untangling the Vascular Web from Alzheimer Disease and Oxidative Stress. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 4-4.	0.6	6
242	The impairment of insulin signaling in Alzheimer's disease. <i>IUBMB Life</i> , 2012, 64, 951-957.	3.6	58
243	Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress. <i>Archives of Medical Research</i> , 2012, 43, 694-698.	3.5	86
244	AGEs/RAGE complex upregulates BACE1 via NF- $\kappa$ B pathway activation. <i>Neurobiology of Aging</i> , 2012, 33, 196.e13-196.e27.	3.2	125
245	$\beta$ -Amyloid 1 $\beta$ 42 induces physiological transcriptional regulation of BACE1. <i>Journal of Neurochemistry</i> , 2012, 122, 1023-1031.	4.0	22
246	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	11.0	3,158
247	Nuclear and mitochondrial DNA oxidation in Alzheimer's disease. <i>Free Radical Research</i> , 2012, 46, 565-576.	3.3	46
248	Mark Smith: Pioneer of Alzheimer Disease Research. <i>Neurotoxicity Research</i> , 2012, 22, 181-181.	2.7	0
249	Structures and free energy landscapes of aqueous zinc(II)-bound amyloid- $\beta$ (1 $\beta$ 40) and zinc(II)-bound amyloid- $\beta$ (1 $\beta$ 42) with dynamics. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 927-938.	2.8	40
250	Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-7.	2.5	46
251	The Contribution of the Amyloid Hypothesis to the Understanding of Alzheimer's Disease: A Critical Overview. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-2.	2.5	1
252	Glycogen Synthase Kinase 3: A Point of Integration in Alzheimer's Disease and a Therapeutic Target?. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-4.	2.5	16

#	ARTICLE	IF	CITATIONS
253	Alzheimer's Disease: Advances for a New Century. Journal of Alzheimer's Disease, 2012, 33, S1-S1.	2.7	2
254	Journal of Huntington's Disease – The Family Gets Bigger. Journal of Alzheimer's Disease, 2012, 30, 735-735.	2.7	0
255	Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!. CNS and Neurological Disorders - Drug Targets, 2012, 11, 81-85.	1.6	35
256	Inge Grundke-Iqbal: A Legacy of Tau in the Etiology of Alzheimer Disease (1937–2012). Journal of Alzheimer's Disease, 2012, 33, 1-2.	2.7	1
257	Abnormal Mitochondrial Dynamics in the Pathogenesis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S253-S262.	2.7	168
258	Oxidative Damage to RNA in Aging and Neurodegenerative Disorders. Neurotoxicity Research, 2012, 22, 231-248.	2.7	165
259	Mitochondrial Importance in Alzheimer's, Huntington's and Parkinson's Diseases. Advances in Experimental Medicine and Biology, 2012, 724, 205-221.	0.0	58
260	The role of iron as a mediator of oxidative stress in Alzheimer disease. BioFactors, 2012, 38, 133-138.	5.5	65
261	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. Journal of Neurochemistry, 2012, 120, 419-429.	4.0	438
262	Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover. Free Radical Biology and Medicine, 2012, 52, 699-704.	4.5	39
263	Editorial - Chronic or Late Lyme Neuroborreliosis: Present and Future. The Open Neurology Journal, 2012, 6, 78-78.	0.4	3
264	A Pleotrophic Age for Alzheimer and Parkinson disease. , 2012, 02, .		0
265	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0
266	R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protection in Alzheimer's Disease. Oxidative Stress and Disease, 2012, , 455-467.	0.0	0
267	In Vivo and In Silico Evidence: Hippocampal Cholesterol Metabolism Decreases with Aging and Increases with Alzheimers Disease – Modeling Brain Aging and Disease. , 2011, , .		3
268	Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Molecular BioSystems, 2011, 7, 1891.	2.8	11
269	Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?. Ageing Research Reviews, 2011, 10, 264-273.	11.2	198
270	Frontiers in Alzheimer's disease therapeutics. Therapeutic Advances in Chronic Disease, 2011, 2, 9-23.	2.6	27



#	ARTICLE	IF	CITATIONS
271	Role of metal dyshomeostasis in Alzheimer's disease. <i>Metallomics</i> , 2011, 3, 267.	2.5	276
272	Mark A. Smith: Scholar and Innovator. <i>European Journal of Histochemistry</i> , 2011, 55, 2.	1.6	1
273	Imaging the Alzheimer Brain. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 1-27.	2.7	41
274	Mark Anthony Smith (1965–2010): Visionary, Alzheimer Researcher, and Editor-in-Chief of the Journal of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 1-2.	2.7	7
275	Journal of Parkinson's Disease – Birth of JAD's New Sister. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 1-1.	2.7	7
276	Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 1-2.	2.7	13
277	Alzheimer's disease therapy: a moving target. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 457-458.	0.2	0
278	Mark A. Smith, PhD: Renegade Scientist and Visionary. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 495-497.	1.8	0
279	The Cell Cycle Regulator Phosphorylated Retinoblastoma Protein Is Associated With Tau Pathology in Several Tauopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 578-587.	1.8	32
280	The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention. <i>Current Pharmaceutical Design</i> , 2011, 17, 3374-3380.	1.9	30
281	DLP1-dependent mitochondrial fragmentation mediates methylphenylpyridinium toxicity in neurons: implications for Parkinson's disease. <i>Aging Cell</i> , 2011, 10, 807-823.	6.8	114
282	The origin of oxidative stress in neurodegenerative disease: Mark Anthony Smith 1965–2010. <i>Free Radical Biology and Medicine</i> , 2011, 51, 248-249.	4.5	3
283	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 23-26.	2.9	13
284	Intrahippocampal Amyloid- $\beta$ (1-40) Injections Injure Medial Septal Neurons in Rats. <i>Current Alzheimer Research</i> , 2011, 8, 832-840.	1.5	20
285	Amyloid- $\beta$ peptide structure in aqueous solution varies with fragment size. <i>Journal of Chemical Physics</i> , 2011, 135, 205101.	3.1	48
286	Mark A. Smith. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 369-370.	1.3	0
287	Neurodegenerative Processes In Alzheimer's Disease: An Overview of Pathogenesis With Strategic Biomarker Potential. <i>Future Neurology</i> , 2011, 6, 173-185.	0.5	0
288	A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. <i>Laboratory Investigation</i> , 2011, 91, 1777-1786.	3.9	44

#	ARTICLE	IF	CITATIONS
289	Oxidative Stress and Balance in Neurodegenerative Diseases. , 2011, , 10-12.		1
290	Oxidative Stress in Alzheimer's Disease: A Critical Appraisal of the Causes and the Consequences. , 2011, , 211-220.		2
291	New Insights into the Mechanisms of Mitochondrial Preconditioning-Triggered Neuroprotection. Current Pharmaceutical Design, 2011, 17, 3381-3389.	1.9	28
292	Neurofilamentopathy in Neurodegenerative Diseases. The Open Neurology Journal, 2011, 5, 58-62.	0.4	57
293	Transcriptome-To-Metabolome, Biosimulation Reveals Human Hippocampal Hypometabolism with Age and Alzheimer's Disease. International Journal of Knowledge Discovery in Bioinformatics, 2011, 2, 1-18.	0.8	3
294	Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities. Advances in Neurobiology, 2011, , 607-631.	0.0	0
295	Association of Mitochondrial Signaling in Alzheimer's Disease and Hypoxia. , 2011, , 50-61.		0
296	Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs. Therapy: Open Access in Clinical Medicine, 2011, 8, 475-479.	0.2	0
297	Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 363-372.	2.7	362
298	Elevation of $\beta$ -Amyloid 1-42 Autoantibodies in the Blood of Amnesic Patients With Mild Cognitive Impairment. Archives of Neurology, 2010, 67, 867-72.	4.5	30
299	Antioxidant approaches for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2010, 10, 1201-1208.	2.8	104
300	Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease. RSC Drug Discovery Series, 2010, , 97-107.	0.0	0
301	Intraneuronal amyloid $\beta$ accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiology of Disease, 2010, 37, 731-737.	4.5	89
302	Dissociated amyloid- $\beta$ antibody levels as a serum biomarker for the progression of Alzheimer's disease: A population-based study. Experimental Gerontology, 2010, 45, 47-52.	2.9	31
303	Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers. Hippocampus, 2010, 20, 902-905.	2.2	32
304	Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein. Annals of Neurology, 2010, 68, 162-172.	5.8	205
305	Paraffin-embedded tissue (PET) blot method: Application to Alzheimer disease. Journal of Neuroscience Methods, 2010, 190, 244-247.	2.6	7
306	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. Cell Research, 2010, 20, 397-399.	12.2	14

#	ARTICLE	IF	CITATIONS
307	Widespread distribution of reticulon-3 in various neurodegenerative diseases. <i>Neuropathology</i> , 2010, 30, 574-579.	1.3	18
308	Mitochondria and Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S253-S253.	2.7	2
309	Mitochondrial preconditioning: a potential neuroprotective strategy. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	3.5	29
310	A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S401-S412.	2.7	141
311	Prospects on the Origin of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 669-672.	2.7	3
312	Mitochondria: The Missing Link Between Preconditioning and Neuroprotection. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S475-S485.	2.7	49
313	Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy. , 2010, , 305-323.		5
314	Potential Role of Iron in a Mediterranean-style Diet. <i>Archives of Neurology</i> , 2010, 67, 1286.	4.5	3
315	Upregulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 771-775.	2.7	19
316	NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid- $\beta$ Peptide. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 57-66.	2.7	100
317	Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. <i>Redox Report</i> , 2010, 15, 161-168.	4.6	107
318	Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. <i>Free Radical Research</i> , 2010, 44, 734-741.	3.3	1
319	Biomarkers in Alzheimer's Disease: Past, Present and Future. <i>Biomarkers in Medicine</i> , 2010, 4, 15-26.	1.4	58
320	Detection and Localization of Markers of Oxidative Stress by In Situ Methods: Application in the Study of Alzheimer Disease. <i>Methods in Molecular Biology</i> , 2010, 610, 419-434.	0.0	57
321	Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. <i>Neuroscience Letters</i> , 2010, 468, 267-271.	2.1	145
322	Abnormal mitochondrial dynamics and neurodegenerative diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 135-142.	3.8	233
323	Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 2-10.	3.8	617
324	Mitochondria: A therapeutic target in neurodegeneration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 212-220.	3.8	248

#	ARTICLE	IF	CITATIONS
325	Mathematical modeling of microtubule dynamics: Insights into physiology and disease. Progress in Neurobiology, 2010, 92, 478-483.	5.8	21
326	Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology, 2010, 59, 290-294.	4.2	443
327	Signaling effect of amyloid- $\beta$ 242 on the processing of A $\beta$ 2PP. Experimental Neurology, 2010, 221, 18-25.	4.1	53
328	Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy. Methods in Molecular Biology, 2010, 610, 123-144.	0.0	90
329	Autophagy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2010, 10, 1209-1218.	2.8	51
330	Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Review of Neurotherapeutics, 2010, 10, 683-691.	2.8	62
331	Mitochondrial Dynamics in Alzheimer's Disease. Drugs and Aging, 2010, 27, 181-192.	3.0	89
332	A Novel Endogenous Indole Protects Rodent Mitochondria and Extends Rotifer Lifespan. PLoS ONE, 2010, 5, e10206.	2.5	42
333	Gonadotropin effects. , 2009, , 251-274.		0
334	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals, 2009, 2, 250-286.	3.9	9
335	Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease. Journal of Neuroscience, 2009, 29, 9090-9103.	3.8	1,031
336	Molecular Pathogenesis of Alzheimer's Disease: Reductionist versus Expansionist Approaches. International Journal of Molecular Sciences, 2009, 10, 1386-1406.	4.2	44
337	Is Alzheimers Disease a Myth? When is Disease a Disease?. Current Alzheimer Research, 2009, 6, 82-82.	1.5	0
338	Natural Oxidant Balance in Parkinson Disease. Archives of Neurology, 2009, 66, 1445.	4.5	4
339	Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. Journal of Cellular and Molecular Medicine, 2009, 13, 320-333.	3.6	105
340	Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. Journal of Cellular and Molecular Medicine, 2009, 13, 853-865.	3.6	18
341	The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Research, 2009, 1249, 244-250.	2.3	37
342	Altered redox balance in disease: Can we change the new equilibria?. Annals of Neurology, 2009, 65, 121-123.	5.8	7

#	ARTICLE	IF	CITATIONS
343	Neuroprotective effect of cocoa flavonoids on in vitro oxidative stress. <i>European Journal of Nutrition</i> , 2009, 48, 54-61.	4.0	57
344	RNA oxidation in Alzheimer disease and related neurodegenerative disorders. <i>Acta Neuropathologica</i> , 2009, 118, 151-166.	7.9	135
345	Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. <i>Journal of Bioenergetics and Biomembranes</i> , 2009, 41, 433-440.	2.3	65
346	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2009, 4, 32.	11.8	34
347	The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 $\alpha$ . <i>Journal of Neurochemistry</i> , 2009, 108, 1045-1056.	4.0	219
348	The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2009, 109, 153-159.	4.0	251
349	The essential role of ERK in 4-oxo $\alpha$ -2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells. <i>Journal of Neurochemistry</i> , 2009, 108, 1434-1441.	4.0	13
350	Tau is an inhibitor of deacetylase HDAC6 function. <i>Journal of Neurochemistry</i> , 2009, 109, 1756-1766.	4.0	154
351	Insulin is a Two-Edged Knife on the Brain. <i>Journal of Alzheimer's Disease</i> , 2009, 18, 483-507.	2.7	125
352	A novel approach to the identification and quantitative elemental analysis of amyloid deposits: Insights into the pathology of Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2009, 382, 91-95.	2.2	96
353	Getting the iron out: Phlebotomy for Alzheimer's disease?. <i>Medical Hypotheses</i> , 2009, 72, 504-509.	1.5	35
354	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. <i>Neurochemistry International</i> , 2009, 54, 84-88.	3.9	125
355	Nanoparticle-chelator conjugates as inhibitors of amyloid- $\beta$ aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. <i>Neuroscience Letters</i> , 2009, 455, 187-190.	2.1	139
356	Down-regulation of aminolevulinatase synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 460, 180-184.	2.1	18
357	Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 461, 302-305.	2.1	8
358	Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. <i>Progress in Brain Research</i> , 2009, 180, 97-108.	3.9	20
359	Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimer's Disease. , 2009, , 103-113.		3
360	Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. <i>Free Radical Research</i> , 2009, 43, 156-164.	3.3	66

#	ARTICLE	IF	CITATIONS
361	All- <i>trans</i> retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Review of Neurotherapeutics, 2009, 9, 1615-1621.	2.8	106
362	Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 731-740.	2.7	115
363	The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse. American Journal of Pathology, 2009, 174, 891-897.	4.1	84
364	Mitochondrial Drugs for Alzheimer Disease. Pharmaceuticals, 2009, 2, 287-298.	3.9	16
365	Oxidative Stress in Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 763-774.	2.7	249
366	Food Antioxidants and Alzheimer's Disease. Oxidative Stress and Disease, 2009, , .	0.0	0
367	Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid- $\beta$ Protein Precursor and Amyloid- $\beta$ . Journal of Alzheimer's Disease, 2009, 18, 447-452.	2.7	140
368	2009 Award Recipients-Peter C. Burger, MD, Pierluigi Gambetti, MD, and Nicholas K. Gonatas, MD. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1244-1246.	1.8	0
369	Metal Chelators Coupled with Nanoparticles as Potential Therapeutic Agents for Alzheimer's Disease. Journal of Nanoneuroscience, 2009, 1, 42-55.	0.5	36
370	Oxidative Stress in Parkinson's Disease. The Open Pathology Journal, 2009, 3, 38-42.	0.9	6
371	Cellular Respiration and Tumor Suppressor Genes. , 2009, , 131-144.		0
372	Oxidative Stress Associated Signal Transduction Cascades in Alzheimer Disease. Contemporary Clinical Neuroscience, 2009, , 121-136.	0.0	0
373	Alzheimer Disease: Oxidative Stress and Compensatory Responses. Contemporary Clinical Neuroscience, 2009, , 109-120.	0.0	0
374	Oxidative stress activates a positive feedback between the $\beta$ - and $\gamma$ -secretase cleavages of the amyloid precursor protein. Journal of Neurochemistry, 2008, 104, 683-695.	4.0	296
375	Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 2008, 30, 209-215.	2.9	140
376	Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Molecular Neurodegeneration, 2008, 3, 13.	11.8	67
377	Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Journal of Neurochemistry, 2008, 79, 311-318.	4.0	146
378	Physiological regulation of tau phosphorylation during hibernation. Journal of Neurochemistry, 2008, 105, 2098-2108.	4.0	81

#	ARTICLE	IF	CITATIONS
379	Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. <i>Journal of Neurochemistry</i> , 2008, 106, 1350-1356.	4.0	48
380	Redox active iron accumulation in aceruloplasminemia. <i>Neuropathology</i> , 2008, 28, 466-471.	1.3	47
381	Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. <i>International Journal of Experimental Pathology</i> , 2008, 89, 81-90.	1.3	114
382	Nucleic acid oxidation in Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1493-1505.	4.5	189
383	Current approaches in the treatment of Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 199-207.	5.8	140
384	Oxidative Stress and Neurotoxicity. <i>Chemical Research in Toxicology</i> , 2008, 21, 172-188.	3.5	727
385	Alzheimer Disease Pathology As a Host Response. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 523-531.	1.8	153
386	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. <i>Autophagy</i> , 2008, 4, 151-175.	11.0	2,086
387	Antibodies to Potato Virus Y Bind the Amyloid $\beta$ Peptide. <i>Journal of Biological Chemistry</i> , 2008, 283, 22550-22556.	3.5	24
388	Stem cell niches as clinical targets: the future of anti-ischemic therapy?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 590-591.	1.9	9
389	Menopause, Estrogen, and Gonadotropins in Alzheimer's Disease. <i>Advances in Clinical Chemistry</i> , 2008, 45, 139-153.	3.3	10
390	Cerebrotendinous xanthomatosis: a critical update. <i>Future Neurology</i> , 2008, 3, 491-501.	0.5	2
391	Nonestrogen-Based Hormonal Therapies for Alzheimer's Disease. <i>Future Neurology</i> , 2008, 3, 399-407.	0.5	0
392	From Aging to Alzheimer's Disease: Unveiling "The Switch" with the Senescence-Accelerated Mouse Model (SAMP8). <i>Journal of Alzheimer's Disease</i> , 2008, 15, 615-624.	2.7	181
393	Three-Dimensional Tomographic Imaging and Characterization of Iron Compounds within Alzheimer's Plaque Core Material. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 235-245.	2.7	138
394	Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2008, 7, 3-10.	1.6	137
395	Phosphorylated Tau: Toxic, Protective, or None of the Above. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 377-383.	2.7	80
396	Alzheimer's Disease: Cerebrovascular Dysfunction, Oxidative stress, and Advanced Clinical Therapies. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 199-210.	2.7	78

#	ARTICLE	IF	CITATIONS
397	Sublethal RNA Oxidation as a Mechanism for Neurodegenerative Disease. International Journal of Molecular Sciences, 2008, 9, 789-806.	4.2	35
398	Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer's disease. Vascular Health and Risk Management, 2008, Volume 4, 721-730.	2.3	54
399	Transgenic Mouse Models of Alzheimer's Disease. Frontiers in Neuroscience, 2008, , 1-18.	0.0	5
400	Antioxidant Therapy in Alzheimers Disease: Theory and Practice. Mini-Reviews in Medicinal Chemistry, 2008, 8, 1395-1406.	2.6	131
401	The Autistic Phenotype Exhibits a Remarkably Localized Modification of Brain Protein by Products of Free Radical-Induced Lipid Oxidation. American Journal of Biochemistry and Biotechnology, 2008, 4, 61-72.	0.4	48
402	The primary pathogenetic role of vascular hypoperfusion, mitochondria failure and oxidative stress in aging and Alzheimer disease. FASEB Journal, 2008, 22, 167.3.	0.5	0
403	Antibody-Antigen Dissociation: A Novel Diagnostic Tool in Alzheimer Disease. FASEB Journal, 2008, 22, 167.10.	0.5	0
404	Neurodegenerative Phenotypes Induced by MYC-Driven Neuronal Cell Cycle Re-entry: Relevance to Alzheimer Disease. FASEB Journal, 2008, 22, 167.6.	0.5	0
405	Role of Oxidative Insult and Neuronal Survival in Alzheimer's and Parkinson's Diseases. , 2008, , 133-148.		0
406	Two Hits and You're Out? A Novel Mechanistic Hypothesis of Alzheimer Disease. , 2008, , 191-204.		2
407	Oxidative Stress Is an Early Event in Hydrostatic Pressure-Induced Retinal Ganglion Cell Damage. , 2007, 48, 4580.		149
408	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	2.8	42
409	Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain. Current Alzheimer Research, 2007, 4, 67-72.	1.5	64
410	Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants. Mini-Reviews in Medicinal Chemistry, 2007, 7, 171-180.	2.6	59
411	Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia. Redox Report, 2007, 12, 257-266.	4.6	8
412	Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Report, 2007, 12, 119-124.	4.6	12
413	Amyloid-β in Alzheimer Disease: The Null versus the Alternate Hypotheses. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 823-829.	2.4	144
414	The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis. Clinical Medicine and Research, 2007, 5, 177-183.	0.9	40



#	ARTICLE	IF	CITATIONS
415	Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease. , 2007, , 451-466.		2
416	Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 143-152.	2.7	95
417	Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 525-532.	1.8	139
418	Evidence for the Role of Luteinizing Hormone in Alzheimer Disease. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 300-303.	1.3	19
419	Alzheimer disease, the two-hit hypothesis: An update. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 494-502.	3.8	257
420	Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. Molecular and Cellular Endocrinology, 2007, 260-262, 271-275.	3.3	18
421	Increases in luteinizing hormone are associated with declines in cognitive performance. Molecular and Cellular Endocrinology, 2007, 269, 107-111.	3.3	105
422	Treating the Lesions, Not the Disease. American Journal of Pathology, 2007, 170, 1457-1459.	4.1	14
423	The Key Role of Oxidative Stress in Alzheimer's Disease. , 2007, , 267-281.		14
424	Three Histidine Residues of Amyloid- $\beta$ Peptide Control the Redox Activity of Copper and Iron. Biochemistry, 2007, 46, 12737-12743.	2.6	176
425	Vascular oxidative stress in Alzheimer disease. Journal of the Neurological Sciences, 2007, 257, 240-246.	0.6	166
426	Lipoic Acid and N-acetyl Cysteine Decrease Mitochondrial-Related Oxidative Stress in Alzheimer Disease Patient Fibroblasts. Journal of Alzheimer's Disease, 2007, 12, 195-206.	2.7	177
427	Sir Martin Roth â€™ A Debt of Gratitude. Journal of Alzheimer's Disease, 2007, 11, 1-1.	2.7	0
428	Mitochondrial autophagocytosis in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 434.	1.8	0
429	c-Jun phosphorylation in Alzheimer disease. Journal of Neuroscience Research, 2007, 85, 1668-1673.	3.0	76
430	Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Molecular Neurodegeneration, 2007, 2, 2.	11.8	58
431	Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid- $\beta$ peptide. Free Radical Biology and Medicine, 2007, 43, 1552-1559.	4.5	82
432	Insights into amyloid- $\beta$ -induced mitochondrial dysfunction in Alzheimer disease. Free Radical Biology and Medicine, 2007, 43, 1569-1573.	4.5	95

#	ARTICLE	IF	CITATIONS
433	The role of novel chitin-like polysaccharides in Alzheimer disease. <i>Neurotoxicity Research</i> , 2007, 12, 269-274.	2.7	35
434	Increased Expression of p130 in Alzheimer Disease. <i>Neurochemical Research</i> , 2007, 32, 639-644.	3.3	13
435	Indices of Metabolic Dysfunction and Oxidative Stress. <i>Neurochemical Research</i> , 2007, 32, 717-722.	3.3	23
436	Iron: The Redox-active Center of Oxidative Stress in Alzheimer Disease. <i>Neurochemical Research</i> , 2007, 32, 1640-1645.	3.3	170
437	The Pathology of Alzheimer Disease Elicits an In Vivo Immunological Response. <i>American Journal of Immunology</i> , 2007, 3, 10-14.	0.1	2
438	BRCA1 May Modulate Neuronal Cell Cycle Re-Entry in Alzheimer Disease. <i>International Journal of Medical Sciences</i> , 2007, 4, 140-145.	2.6	59
439	The Role of Oxidative Damage to Nucleic Acids in the Pathogenesis of Neurological Disease. , 2007, , 123-140.		2
440	The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics. , 2007, , 194-211.		0
441	Mitochondrial Autophagocytosis in Alzheimer Disease. <i>FASEB Journal</i> , 2007, 21, A73.	0.5	0
442	Lipoic Acid and Nâ€Acetyl Cysteine Protect Against Mitochondrialâ€Related Oxidative Stress in Fibroblasts from Alzheimer Disease Patients. <i>FASEB Journal</i> , 2007, 21, .	0.5	0
443	Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 434.	1.8	0
444	Protein Misfolding in Alzheimer's Disease. <i>Enzyme Inhibitors Series</i> , 2007, , .	0.0	0
445	The Fallacy of Amyloid and Cognition in Alzheimer's Disease. <i>Drugs and Aging</i> , 2006, 23, 179.	3.0	1
446	Antioxidant protection and neurodegenerative disease: The role of amyloid- $\beta$ and tau. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 126-130.	2.0	64
447	The Estrogen Myth. <i>Drugs in R and D</i> , 2006, 7, 187-193.	2.2	25
448	Amyloid- $\beta$ Vaccination: Testing the Amyloid Hypothesis?. <i>American Journal of Pathology</i> , 2006, 169, 738-739.	4.1	20
449	Telomeres and telomerase in Alzheimer's disease: Epiphenomena or a new focus for therapeutic strategy?. <i>Alzheimer's and Dementia</i> , 2006, 2, 164-168.	0.7	68
450	Commentary on â€Perspective on a pathogenesis and treatment of Alzheimer's disease.â€Therapeutic strategies for Alzheimer's disease: The need for a new era of innovation. <i>Alzheimer's and Dementia</i> , 2006, 2, ALZJJALZ200607002.	0.7	0

#	ARTICLE	IF	CITATIONS
451	Emerging evidence for the neuroprotective role of $\alpha$ -synuclein. <i>Experimental Neurology</i> , 2006, 200, 1-7.	4.1	30
452	Luteinizing hormone modulates cognition and amyloid- $\beta$ deposition in Alzheimer APP transgenic mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 447-452.	3.8	169
453	Malignant glioma progression and nitric oxide. <i>Neurochemistry International</i> , 2006, 49, 764-768.	3.9	42
454	Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. <i>Neuroscience Letters</i> , 2006, 406, 189-193.	2.1	176
455	Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. <i>Neurobiology of Aging</i> , 2006, 27, 1588-1594.	3.2	27
456	Compensatory responses induced by oxidative stress in Alzheimer disease. <i>Biological Research</i> , 2006, 39, 7-13.	3.6	40
457	Solving the insoluble. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 301-304.	2.7	4
458	Therapeutic potential of oxidative stress reduction in Alzheimer's disease. <i>Future Neurology</i> , 2006, 1, 1-4.	0.5	4
459	Involvement of Oxidative Stress in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 631-641.	1.8	496
460	Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 147-153.	2.7	170
461	Steroidogenic Acute Regulatory Protein (StAR): Evidence of Gonadotropin-Induced Steroidogenesis in Alzheimer Disease. <i>Molecular Neurodegeneration</i> , 2006, 1, 14.	11.8	37
462	LRRK2 in Parkinson's disease and dementia with Lewy bodies. <i>Molecular Neurodegeneration</i> , 2006, 1, 17.	11.8	41
463	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. <i>Acta Neuropathologica</i> , 2006, 111, 503-509.	7.9	127
464	Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy. <i>Age</i> , 2006, 28, 85-91.	2.9	1
465	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. <i>Neurotoxicity Research</i> , 2006, 10, 43-56.	2.7	76
466	Presenilin mutation: A deadly first hit in Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2006, 40, 737-739.	4.5	6
467	Amyloid- $\beta$ , BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression" Free Radical Biology and Medicine, 2006, 41, 188-189.	4.5	6
468	Aberrant localization of importin $\beta$ 1 in hippocampal neurons in Alzheimer disease. <i>Brain Research</i> , 2006, 1124, 1-4.	2.3	54

#	ARTICLE	IF	CITATIONS
469	The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease. <i>Mechanisms of Ageing and Development</i> , 2006, 127, 501-506.	4.6	19
470	Ectopic expression of phospho-Smad2 in Alzheimer's disease: Uncoupling of the transforming growth factor- $\beta^2$ pathway?. <i>Journal of Neuroscience Research</i> , 2006, 84, 1856-1861.	3.0	69
471	LRRK2 protein is a component of lewy bodies. <i>Annals of Neurology</i> , 2006, 60, 617-618.	5.8	57
472	Age-Related Loss of the DNA Repair Response Following Exposure to Oxidative Stress. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 427-434.	3.7	44
473	Therapeutic options in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 897-910.	2.8	41
474	Heme Deficiency in Alzheimer's Disease: A Possible Connection to Porphyria. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-5.	2.3	15
475	Apoptosis in Alzheimer Disease: A Mathematical Improbability. <i>Current Alzheimer Research</i> , 2006, 3, 393-396.	1.5	91
476	The Cell Cycle and Hormonal Fluxes in Alzheimer Disease: A Novel Therapeutic Target. <i>Current Pharmaceutical Design</i> , 2006, 12, 691-697.	1.9	21
477	Neurodegenerative Diseases: Mechanisms and Therapies. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-2.	2.3	1
478	Foreword: Apoptotic Mechanisms in Neurodegenerative Diseases. <i>Current Alzheimer Research</i> , 2006, 3, 267-267.	1.5	0
479	Amyloid Beta: The Alternate Hypothesis. <i>Current Alzheimer Research</i> , 2006, 3, 75-80.	1.5	100
480	Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-8.	2.3	13
481	Oxidative Damage to RNA in Neurodegenerative Diseases. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-6.	2.3	100
482	Neuropathology in Alzheimer's Disease: Awakening from a Hundred-Year-Old Dream. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2006, 2006, pe10-pe10.	0.3	11
483	Cell Cycle Activation and the Amyloid- $\beta^2$ Protein in Alzheimer's Disease. , 2006, , 299-308.		0
484	Neurogenesis in Alzheimer's Disease. , 2006, , 359-370.		0
485	The Changing landscape of Alzheimer's disease: From Insoluble to Soluble and from Pathogen to Protector. , 2006, , 367-369.		0
486	Gender Differences in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 95-99.	1.3	31

#	ARTICLE	IF	CITATIONS
487	Insulin signaling, diabetes mellitus and risk of Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 81-84.	2.7	45
488	Nuclear microscopy of diffuse plaques in the brains of transgenic mice. <i>Nuclear Instruments &amp; Methods in Physics Research B</i> , 2005, 231, 326-332.	1.4	4
489	Oxidative Imbalance in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2005, 31, 205-218.	4.1	127
490	Amyloid- $\beta^2$ in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. <i>International Journal of Experimental Pathology</i> , 2005, 86, 133-138.	1.3	54
491	Role of Amyloid- $\beta^2$ in Alzheimer's Disease. <i>International Journal of Experimental Pathology</i> , 2005, 86, 131-131.	1.3	0
492	Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. <i>Free Radical Biology and Medicine</i> , 2005, 38, 746-754.	4.5	117
493	The cell cycle in Alzheimer disease: A unique target for neuropharmacology. <i>Mechanisms of Ageing and Development</i> , 2005, 126, 1019-1025.	4.6	100
494	Introduction: Imaging in Alzheimer's disease. <i>Microscopy Research and Technique</i> , 2005, 67, 113-113.	2.3	0
495	Mitogen- and stress-activated protein kinase 1: Convergence of the ERK and p38 pathways in Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2005, 79, 554-560.	3.0	30
496	MAPKs are differentially modulated in arctic ground squirrels during hibernation. <i>Journal of Neuroscience Research</i> , 2005, 80, 862-868.	3.0	35
497	Redox metals and oxidative abnormalities in human prion diseases. <i>Acta Neuropathologica</i> , 2005, 110, 232-238.	7.9	53
498	Retinoic acid isomers protect hippocampal neurons from amyloid- $\beta^2$ induced neurodegeneration. <i>Neurotoxicity Research</i> , 2005, 7, 243-250.	2.7	39
499	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. <i>Molecular and Cellular Biochemistry</i> , 2005, 278, 203-212.	3.1	28
500	P38 Activation Mediates Amyloid- $\beta^2$ Cytotoxicity. <i>Neurochemical Research</i> , 2005, 30, 791-796.	3.3	43
501	What is aging? What is its role in Alzheimer's disease? What can we do about it?. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 247-253.	2.7	22
502	Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2005, 5, 51-62.	0.5	16
503	Therapeutic Opportunities in Alzheimer Disease: One for all or all for One?. <i>Current Medicinal Chemistry</i> , 2005, 12, 1137-1147.	2.5	49
504	Ferric Cycle Activity and Alzheimer Disease. <i>Current Neurovascular Research</i> , 2005, 2, 261-267.	1.1	14

#	ARTICLE	IF	CITATIONS
505	Oxidative Stress: The Old Enemy in Alzheimers Disease Pathophysiology. Current Alzheimer Research, 2005, 2, 403-408.	1.5	119
506	Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron. Journal of Biological Chemistry, 2005, 280, 20978-20986.	3.5	264
507	Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease. Letters in Drug Design and Discovery, 2005, 2, 479-482.	0.7	6
508	A Second Look into the Oxidant Mechanisms in Alzheimers Disease. Current Neurovascular Research, 2005, 2, 179-184.	1.1	11
509	The End of a Chilean Institute. Science, 2005, 308, 792b-793b.	20.9	0
510	Commentary: "Ceramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" By Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli. Alzheimer's and Dementia, 2005, 1, 51-52.	0.7	3
511	4-Oxo-2-nonenal Is Both More Neurotoxic and More Protein Reactive than 4-Hydroxy-2-nonenal. Chemical Research in Toxicology, 2005, 18, 1219-1231.	3.5	149
512	Tau phosphorylation in Alzheimer's disease: pathogen or protector?. Trends in Molecular Medicine, 2005, 11, 164-169.	7.1	225
513	Alzheimer's disease: an intracellular movement disorder?. Trends in Molecular Medicine, 2005, 11, 391-393.	7.1	18
514	Tau modifiers as therapeutic targets for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 211-215.	3.8	14
515	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 472-480.	3.8	38
516	Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 246-252.	3.8	146
517	Concealment of epitope by reduction and alkylation in prion protein. Biochemical and Biophysical Research Communications, 2005, 326, 652-659.	2.2	14
518	Chronological primacy of oxidative stress in Alzheimer disease. Neurobiology of Aging, 2005, 26, 579-580.	3.2	49
519	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. Journal of the Neurological Sciences, 2005, 229-230, 285-292.	0.6	55
520	Carnosine: A Versatile Antioxidant and Antiglycating Agent. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe12-pe12.	0.3	92
521	Oxidative damage and Alzheimer's disease: Are antioxidant therapies useful?. Drug News and Perspectives, 2005, 18, 5.	1.0	46
522	Ciprofloxacin Does Not Exert Nephrotoxicity in Rats. American Journal of Infectious Diseases, 2005, 1, 145-148.	0.2	0

#	ARTICLE	IF	CITATIONS
523	Amyloid- $\beta$ and $\tau$ in Alzheimer's Disease. <i>Oxidative Stress and Disease</i> , 2005, , 121-129.	0.0	0
524	Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease. <i>Oxidative Stress and Disease</i> , 2005, , 365-372.	0.0	0
525	Oxidative Adaptation in Aging and Alzheimer's Disease. <i>Oxidative Stress and Disease</i> , 2005, , 117-125.	0.0	0
526	Antioxidant Therapies in the Prevention and Treatment of Alzheimer Disease. <i>Oxidative Stress and Disease</i> , 2005, , 131-145.	0.0	1
527	Amyloid- $\beta$ -induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. <i>Journal of Neurochemistry</i> , 2004, 88, 554-563.	4.0	77
528	Oxidative Stress in Aging and Neurodegenerative Diseases: From Biology to Therapy, Perugia, Italy, May 2003. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 115-115.	2.7	0
529	Therapeutic potential of oxidant mechanisms in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 995-1004.	2.8	17
530	Drug Therapy in Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 1911-1913.	30.1	16
531	Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease. <i>Medicinal Chemistry Reviews Online</i> , 2004, 1, 19-23.	0.1	2
532	Assembly In Vitro of Tau Protein and its Implications in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2004, 1, 97-101.	1.5	28
533	Heme Catabolism and Heme Oxygenase in Neurodegenerative Disease. <i>Antioxidants and Redox Signaling</i> , 2004, 6, 888-894.	5.5	34
534	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. <i>Neurological Research</i> , 2004, 26, 547-553.	1.4	28
535	Luteinizing Hormone, a Reproductive Regulator That Modulates the Processing of Amyloid- $\beta$ Precursor Protein and Amyloid- $\beta$ Deposition. <i>Journal of Biological Chemistry</i> , 2004, 279, 20539-20545.	3.5	155
536	Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. <i>Journal of Neurochemistry</i> , 2004, 89, 1224-1232.	4.0	40
537	Neuroprotective properties of Bcl-w in Alzheimer disease. <i>Journal of Neurochemistry</i> , 2004, 89, 1233-1240.	4.0	54
538	Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. <i>Aging Cell</i> , 2004, 3, 41-44.	6.8	87
539	Metal Ions and Neurodegenerative Diseases Paolo Zatta, Editor. World Scientific Publishing Co. Pte. Ltd, Singapore, 2004, pp 400. <i>Aging Cell</i> , 2004, 3, 85-85.	6.8	0
540	Alzheimer's disease: the two-hit hypothesis. <i>Lancet Neurology</i> , The, 2004, 3, 219-226.	10.4	403

#	ARTICLE	IF	CITATIONS
541	Homocysteine and Alzheimer's disease: a modifiable risk?. <i>Free Radical Biology and Medicine</i> , 2004, 36, 1471-1475.	4.5	52
542	Accelerated $\beta$ -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. <i>Brain Research</i> , 2004, 1013, 51-59.	2.3	80
543	Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2004, 107, 365-371.	7.9	62
544	Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. <i>Journal of Pathology</i> , 2004, 203, 603-608.	4.5	50
545	Distribution, levels, and activation of MEK1 in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2004, 86, 136-142.	4.0	56
546	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2004, 75, 698-703.	3.0	64
547	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid- $\beta$ . <i>Biochemistry</i> , 2004, 43, 560-568.	2.6	364
548	In Situ Localization of Nonenzymatic Peroxidase-Like Activity of Tissue-Bound Transition Metals. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et al ]</i> , 2004, 20, Unit17.4.	1.3	2
549	Mitochondrial failures in Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2004, 19, 345-352.	2.0	112
550	Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. <i>Neurobiology of Aging</i> , 2004, 25, 599-602.	3.2	55
551	Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. <i>Mitochondrion</i> , 2004, 4, 649-663.	3.6	79
552	Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. <i>Neurobiology of Disease</i> , 2004, 17, 108-113.	4.5	141
553	Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. <i>Ageing Research Reviews</i> , 2004, 3, 319-326.	11.2	95
554	Oxidative stress signalling in Alzheimer's disease. <i>Brain Research</i> , 2004, 1000, 32-39.	2.3	379
555	Alzheimer disease: Evidence for a central pathogenic role of iron-mediated reactive oxygen species. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 165-169.	2.7	102
556	Perspectives on the Amyloid- $\beta$ Cascade Hypothesis. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 137-145.	2.7	57
557	Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimers Disease. <i>CNS and Neurological Disorders</i> , 2004, 3, 281-285.	3.6	33
558	Nutritional Antioxidants, Vitamins, Cognition, and Neurodegenerative Disease. , 2004, , 813-823.		0



#	ARTICLE	IF	CITATIONS
559	Mechanisms Involved in Gender Differences in Alzheimer's Disease: The Role of Leuteinizing and Follicle Stimulating Hormones. , 2004, , 1234-1237.		3
560	Tipping the Apoptotic Balance in Alzheimer's Disease: The Abortosis Concept. Cell Biochemistry and Biophysics, 2003, 39, 249-256.	1.8	19
561	A metabolic basis for Alzheimer disease. Neurochemical Research, 2003, 28, 1549-1552.	3.3	51
562	Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. BioMetals, 2003, 16, 77-81.	4.0	97
563	Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotoxicity Research, 2003, 5, 491-504.	2.7	135
564	Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?. Acta Neuropathologica, 2003, 105, 524-528.	7.9	158
565	Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathologica, 2003, 106, 552-556.	7.9	67
566	Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants. Free Radical Biology and Medicine, 2003, 34, 1070-1077.	4.5	46
567	Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. Journal of Neuroscience Research, 2003, 71, 863-870.	3.0	121
568	JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 87-93.	4.0	60
569	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 1101-1108.	4.0	303
570	4-Hydroxynonenal contributes to NGF withdrawal-induced neuronal apoptosis. Journal of Neurochemistry, 2003, 85, 999-1005.	4.0	17
571	Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry, 2003, 86, 1312-1312.	4.0	3
572	Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell, 2003, 2, 105-110.	6.8	89
573	Metal Binding and Oxidation of Amyloid- $\beta^2$ within Isolated Senile Plaque Cores: A Raman Microscopic Evidence. Biochemistry, 2003, 42, 2768-2773.	2.6	552
574	Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of $\beta$ , Filament Formation. American Journal of Pathology, 2003, 162, 1623-1627.	4.1	298
575	Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Molecular Aspects of Medicine, 2003, 24, 305-313.	6.8	96
576	Role of high mobility group protein-1 (HMG1) in amyloid- $\beta^2$ homeostasis. Biochemical and Biophysical Research Communications, 2003, 301, 699-703.	2.2	86

#	ARTICLE	IF	CITATIONS
577	Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 251-254.	5.0	42
578	Possible involvement of Wiskott's Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease. Neuroscience Letters, 2003, 346, 149-152.	2.1	21
579	Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Research Reviews, 2003, 43, 1-16.	9.0	276
580	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Research Reviews, 2003, 43, 164-178.	9.0	55
581	Estrogen Replacement and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1100.	7.0	18
582	Oxidative Stress and Neuronal Adaptation in Alzheimer Disease: The Role of SAPK Pathways. Antioxidants and Redox Signaling, 2003, 5, 571-576.	5.5	67
583	Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Report, 2003, 8, 129-133.	4.6	4
584	Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurological Research, 2003, 25, 665-674.	1.4	94
585	Cerebral Hemorrhage and Amyloid-β. Science, 2003, 299, 1014a-1014.	20.9	23
586	Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 293-298.	0.2	4
587	Functional Implications of Antiestrogen Induction of Quinone Reductase: Inhibition of Estrogen-Induced Deoxyribonucleic Acid Damage. Molecular Endocrinology, 2003, 17, 1344-1355.	3.4	43
588	Hypoperfusion, Mitochondria Failure, Oxidative Stress, and Alzheimer Disease. Journal of Biomedicine and Biotechnology, 2003, 2003, 162-163.	2.3	28
589	Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?. Brain Pathology, 2003, 13, 630-638.	4.2	24
590	Nanoparticles for the Treatment of Alzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives. , 2003, , .		0
591	Metal-Catalyzed Redox Activity in Neurodegenerative Disease. , 2003, , 1-14.		1
592	Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimer's Disease. Oxidative Stress and Disease, 2003, , .	0.0	0
593	High Molecular Weight Neurofilament Proteins Are Physiological Substrates of Adduction by the Lipid Peroxidation Product Hydroxynonenal. Journal of Biological Chemistry, 2002, 277, 4644-4648.	3.5	122
594	Microglial activation and amyloid-β clearance induced by exogenous heat shock proteins. FASEB Journal, 2002, 16, 601-603.	0.5	303

#	ARTICLE	IF	CITATIONS
595	Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies. <i>NeuroReport</i> , 2002, 13, 2035-2039.	1.2	74
596	Apoptotic and Oxidative Indicators in Alzheimer's Disease. <i>Neuromethods</i> , 2002, , 225-246.	0.0	5
597	Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy. <i>Neurobiology of Disease</i> , 2002, 9, 244-248.	4.5	261
598	Oxidative Damage to Nucleic Acids in Human Prion Disease. <i>Neurobiology of Disease</i> , 2002, 9, 275-281.	4.5	68
599	Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons. <i>Neurobiology of Disease</i> , 2002, 10, 279-288.	4.5	357
600	The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders. <i>CNS Drugs</i> , 2002, 16, 339-352.	6.2	115
601	Predicting the failure of amyloid- $\beta^2$ vaccine. <i>Lancet, The</i> , 2002, 359, 1864-1865.	12.1	52
602	Role of the antioxidant ascorbate in hibernation and warming from hibernation. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2002, 133, 483-492.	2.7	55
603	Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2002, 133, 507-513.	2.7	59
604	The "Down's" Side of Mitochondria. <i>Developmental Cell</i> , 2002, 2, 255-256.	7.0	16
605	The state versus amyloid- $\beta^2$ : the trial of the most wanted criminal in Alzheimer disease. <i>Peptides</i> , 2002, 23, 1333-1341.	2.4	88
606	Senile plaque composition and posttranslational modification of amyloid- $\beta^2$ peptide and associated proteins. <i>Peptides</i> , 2002, 23, 1343-1350.	2.4	133
607	Amyloid- $\beta^2$ , tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?. <i>Neurochemistry International</i> , 2002, 40, 527-531.	3.9	70
608	The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. <i>Neurobiology of Aging</i> , 2002, 23, 855-859.	3.2	43
609	Amyloid- $\beta^2$ : a (life) preserver for the brain. <i>Neurobiology of Aging</i> , 2002, 23, 1097-1099.	3.2	45
610	Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. <i>Neuroscience Letters</i> , 2002, 319, 25-28.	2.1	164
611	Alzheimer Disease and Oxidative Stress. <i>Journal of Biomedicine and Biotechnology</i> , 2002, 2, 120-123.	2.3	391
612	Causes and consequences of oxidative stress in Alzheimer's disease 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease." The full list of papers may be found on the homepage of the journal.. <i>Free Radical Biology and Medicine</i> , 2002, 32, 1049.	4.5	50

#	ARTICLE	IF	CITATIONS
613	Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis1 This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease."The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 173-181.	4.5	70
614	Amyloid- $\beta$ and $\alpha$ , serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology and Medicine, 2002, 33, 1194-1199.	4.5	194
615	Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radical Biology and Medicine, 2002, 33, 1475-1479.	4.5	268
616	Immunized amyloid- $\beta$ vaccine. Journal of Neuroscience Research, 2002, 69, 285-285.	3.0	9
617	Amyloid- $\beta$ : A vascular sealant that protects against hemorrhage?. Journal of Neuroscience Research, 2002, 70, 356-356.	3.0	42
618	Role of mitochondrial dysfunction in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 357-360.	3.0	332
619	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	3.0	123
620	Metals and oxidative homeostasis in Alzheimer's disease. Drug Development Research, 2002, 56, 293-299.	3.0	22
621	Dangers of the amyloid- $\beta$ vaccination. Acta Neuropathologica, 2002, 104, 110-110.	7.9	4
622	The neuroprotective activities of melatonin against the Alzheimer $\beta$ -protein are not mediated by melatonin membrane receptors. Journal of Pineal Research, 2002, 32, 135-142.	7.7	83
623	Call for Elan to publish Alzheimer's trial details. Nature, 2002, 416, 677-677.	36.2	22
624	Involvement of maillard reactions in Alzheimer disease. Neurotoxicity Research, 2002, 4, 191-209.	2.7	100
625	The Role of Oxidative Stress in the Pathophysiology of Cerebrovascular Lesions in Alzheimer's Disease. Brain Pathology, 2002, 12, 21-35.	4.2	147
626	Prion and Alzheimer Diseases: The Road to Pathogenesis is Paved with Copper. , 2002, , 96-101.		1
627	Mitochondrial Abnormalities and Oxidative Imbalance in Neurodegenerative Disease. Science of Aging Knowledge Environment: SAGE KE, 2002, 2002, 16pe-16.	0.3	23
628	Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity. International Journal of Circumpolar Health, 2002, 61, 32-40.	1.2	9
629	Role of Heme Catabolism in Neurodegenerative Diseases. , 2002, , 135-143.		0
630	Neuronal Survival and Death in Alzheimer Disease. Advances in Behavioral Biology, 2002, , 49-57.	0.0	0

#	ARTICLE	IF	CITATIONS
631	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 768-775.	2.2	62
632	Do Neurons Have a Choice in Death?. <i>American Journal of Pathology</i> , 2001, 158, 1-2.	4.1	37
633	Hibernation, a Model of Neuroprotection. <i>American Journal of Pathology</i> , 2001, 158, 2145-2151.	4.1	132
634	A diet at amyloid beta?. <i>Neurobiology of Aging</i> , 2001, 22, 161-163.	3.2	8
635	Copernicus revisited: amyloid beta in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001, 22, 131-146.	3.2	191
636	Mechanisms by which metals promote events connected to neurodegenerative diseases. <i>Brain Research Bulletin</i> , 2001, 55, 125-132.	3.1	97
637	Journal of Alzheimer's Disease Established as a Leading Journal. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 521-523.	2.7	0
638	Hibernation, a Model of Neuroprotection. <i>Scientific World Journal</i> , The, 2001, 1, 108-108.	2.2	3
639	Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. <i>NeuroReport</i> , 2001, 12, 1277-1280.	1.2	42
640	Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. <i>Journal of Neurochemistry</i> , 2001, 76, 565-572.	4.0	163
641	Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2001, 76, 435-441.	4.0	422
642	Induction of NADPH cytochrome P450 reductase by the Alzheimer $\beta$ -protein. Amyloid as a "foreign body"™. <i>Journal of Neurochemistry</i> , 2001, 78, 121-128.	4.0	17
643	Atherosclerotic Lesions Are Associated with Increased Immunoreactivity for Inducible Nitric Oxide Synthase and Endothelin-1 in Thoracic Aortic Intimal Cells of Hyperlipidemic Watanabe Rabbits. <i>Experimental and Molecular Pathology</i> , 2001, 71, 40-54.	2.3	33
644	Abortive apoptosis in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2001, 101, 305-310.	7.9	148
645	Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the "two hit"™ hypothesis. <i>Mechanisms of Ageing and Development</i> , 2001, 123, 39-46.	4.6	300
646	Melatonin reduces interleukin secretion in amyloid- $\beta$ stressed mouse brain slices. <i>Chemico-Biological Interactions</i> , 2001, 134, 101-107.	4.2	31
647	Redox-active iron mediates amyloid- $\beta$ toxicity. <i>Free Radical Biology and Medicine</i> , 2001, 30, 447-450.	4.5	361
648	Erythrocyte, plasma, and serum antioxidant activities in untreated toxic multinodular goiter patients. <i>Free Radical Biology and Medicine</i> , 2001, 30, 665-670.	4.5	30

#	ARTICLE	IF	CITATIONS
649	Active glycation in neurofibrillary pathology of Alzheimer disease: N <sup>ε</sup> -(Carboxymethyl) lysine and hexitol-lysine. <i>Free Radical Biology and Medicine</i> , 2001, 31, 175-180.	4.5	197
650	Oxidative Damage Is the Earliest Event in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 759-767.	1.8	1,691
651	Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease. <i>Current Medicinal Chemistry</i> , 2001, 8, 721-738.	2.5	576
652	Biochemistry of Neurodegeneration. <i>Science</i> , 2001, 291, 595c-597.	20.9	14
653	Mitochondrial Abnormalities in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2001, 21, 3017-3023.	3.8	1,195
654	Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle-Related Events in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 880-888.	1.8	332
655	Oxidative Stress, Antioxidants, and Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2000, 14, S62-S66.	1.3	80
656	Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. <i>The Anatomical Record</i> , 2000, 260, 16-25.	1.6	22
657	How important is oxidative damage? Lessons from Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2000, 28, 831-834.	4.5	249
658	Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?. <i>Mechanisms of Ageing and Development</i> , 2000, 116, 169-179.	4.6	29
659	Evidence for a Novel Heme-Binding Protein, HasAh, in Alzheimer Disease. <i>Antioxidants and Redox Signaling</i> , 2000, 2, 137-142.	5.5	19
660	Overexpression of Heme Oxygenase in Neuronal Cells, the Possible Interaction with Tau. <i>Journal of Biological Chemistry</i> , 2000, 275, 5395-5399.	3.5	171
661	Metabolic, Metallic, and Mitotic Sources of Oxidative Stress in Alzheimer Disease. <i>Antioxidants and Redox Signaling</i> , 2000, 2, 413-420.	5.5	146
662	Histochemical and Immunocytochemical Approaches to the Study of Oxidative Stress. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 93-7.	2.3	12
663	Evidence that the A $\beta$ -Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of A $\beta$ by Zinc. <i>Journal of Biological Chemistry</i> , 2000, 275, 19439-19442.	3.5	368
664	Neuronal Oxidative Stress Precedes Amyloid-A $\beta$ Deposition in Down Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 1011-1017.	1.8	309
665	Lipoperoxidation Is Selectively Involved in Progressive Supranuclear Palsy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 393-397.	1.8	83
666	Protein Disulfide Isomerase in Alzheimer Disease. <i>Antioxidants and Redox Signaling</i> , 2000, 2, 485-489.	5.5	54

#	ARTICLE	IF	CITATIONS
667	Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation. <i>Journal of Cell Biology</i> , 2000, 151, 847-862.	5.2	206
668	Activation of NADPH Oxidase in Alzheimer's Disease Brains. <i>Biochemical and Biophysical Research Communications</i> , 2000, 273, 5-9.	2.2	280
669	Amyloid- $\beta^2$ junkies. <i>Lancet, The</i> , 2000, 355, 757.	12.1	79
670	Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000, 21, 357-361.	3.2	91
671	Oxidative stress in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 139-144.	3.8	680
672	Oxidative damage in Alzheimer's disease: the metabolic dimension. <i>International Journal of Developmental Neuroscience</i> , 2000, 18, 417-421.	1.6	108
673	In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2000, 74, 270-279.	4.0	494
674	In Alzheimer's Disease, Heme Oxygenase Is Coincident with Alz50, an Epitope of $\beta^2$ , Induced by 4-Hydroxy-2-Nonenal Modification. <i>Journal of Neurochemistry</i> , 2000, 75, 1234-1241.	4.0	191
675	RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 1999, 19, 1959-1964.	3.8	715
676	Diet and Oxidative Stress: A Novel Synthesis of Epidemiological Data on Alzheimer's Disease*. <i>Journal of Alzheimer's Disease</i> , 1999, 1, 203-206.	2.7	60
677	RNA Oxidation in Alzheimer and Parkinson Diseases. <i>Rejuvenation Research</i> , 1999, 2, 227-230.	0.2	10
678	Prion Protein Glycosylation Is Sensitive to Redox Change. <i>Journal of Biological Chemistry</i> , 1999, 274, 34846-34850.	3.5	63
679	Redox metals and neurodegenerative disease. <i>Current Opinion in Chemical Biology</i> , 1999, 3, 220-225.	6.4	211
680	Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?. <i>Free Radical Biology and Medicine</i> , 1999, 26, 1508-1512.	4.5	72
681	Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease. <i>Drug Development Research</i> , 1999, 46, 26-33.	3.0	15
682	[10] In situ methods for detection and localization of markers of oxidative stress: Application in neurodegenerative disorders. <i>Methods in Enzymology</i> , 1999, 309, 133-152.	1.7	45
683	Universal Isolation of Cross-Linked Peptides: Application to Neurofibrillary Tangles. <i>Bioconjugate Chemistry</i> , 1999, 10, 112-118.	3.8	6
684	Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons. <i>American Journal of Pathology</i> , 1999, 154, 1423-1429.	4.1	574

#	ARTICLE	IF	CITATIONS
685	Increased Neuronal Glucose-6-phosphate Dehydrogenase and Sulfhydryl Levels Indicate Reductive Compensation to Oxidative Stress in Alzheimer Disease. Archives of Biochemistry and Biophysics, 1999, 370, 236-239.	3.2	117
686	Genetic evidence for oxidative stress in Alzheimer's disease. NeuroReport, 1999, 10, 1355-1357.	1.2	18
687	Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport, 1999, 10, 2411-2415.	1.2	279
688	Serum amyloid P is not present in amyloid $\beta$ deposits of a transgenic animal model. NeuroReport, 1999, 10, 3229-3232.	1.2	20
689	Cytochemical Demonstration of Oxidative Damage in Alzheimer Disease by Immunochemical Enhancement of the Carbonyl Reaction with 2,4-Dinitrophenylhydrazine. Journal of Histochemistry and Cytochemistry, 1998, 46, 731-735.	2.6	234
690	A suicide note from Alzheimer disease neurons?. Nature Medicine, 1998, 4, 897-898.	30.1	107
691	Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Research, 1998, 780, 260-269.	2.3	246
692	Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Research, 1998, 788, 232-236.	2.3	173
693	Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Research, 1998, 791, 63-66.	2.3	70
694	Striation is the characteristic neuritic abnormality in Alzheimer disease. Brain Research, 1998, 813, 329-333.	2.3	32
695	Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radical Biology and Medicine, 1998, 25, 898-902.	4.5	48
696	$Cl^{-}$ -ATPase and $Na^{+}/K^{+}$ -ATPase activities in Alzheimer's disease brains. Neuroscience Letters, 1998, 254, 141-144.	2.1	122
697	What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease?. Journal of Chemical Neuroanatomy, 1998, 16, 35-41.	2.2	37
698	Early Glycoxidation Damage in Brains from Down's Syndrome. Biochemical and Biophysical Research Communications, 1998, 243, 849-851.	2.2	121
699	Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease. Experimental Neurology, 1998, 149, 329-340.	4.1	224
700	Altered Glycosylation Pattern of Proteins in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1998, 57, 905-914.	1.8	54
701	Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. Journal of Alzheimer's Disease, 1998, 1, 45-55.	2.7	185
702	Amyloid $\beta$ Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress. Journal of Neurochemistry, 1998, 70, 2212-2215.	4.0	509



#	ARTICLE	IF	CITATIONS
703	Neuronal Oxidative Stress is a Common Feature of Alzheimer's and Parkinson's Diseases. <i>Advances in Behavioral Biology</i> , 1998, , 77-80.	0.0	1
704	The Role of Oxidative Stress in the Pathological Sequelae of Alzheimer Disease. , 1998, , 195-204.		2
705	Apoptosis and Alzheimer's Disease. , 1998, 282, 1265h-1265.		105
706	Is amyloid $\beta$ -protein glycosylated in Alzheimer's disease?. <i>NeuroReport</i> , 1997, 8, 907-909.	1.2	21
707	Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9866-9868.	7.6	1,280
708	Leuglandin E2 <sup>+</sup> Protein Adducts in Human Plasma and Vasculature. <i>Chemical Research in Toxicology</i> , 1997, 10, 536-545.	3.5	53
709	Mechanisms of Neurotoxicity Associated with Amyloid $\beta$ Deposition and the Role of Free Radicals in the Pathogenesis of Alzheimer's Disease: A Critical Appraisal. <i>Chemical Research in Toxicology</i> , 1997, 10, 518-526.	3.5	110
710	Protocol for quantitative analysis of paired helical filament solubilization: a method applicable to insoluble amyloids and inclusion bodies. <i>Brain Research Protocols</i> , 1997, 1, 247-252.	1.6	5
711	4-Hydroxynonenal-Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1997, 68, 2092-2097.	4.0	914
712	APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. <i>Neurobiology of Aging</i> , 1996, 17, 153-171.	3.2	50
713	Early contribution of oxidative glycation in Alzheimer disease. <i>Neuroscience Letters</i> , 1996, 217, 210-211.	2.1	29
714	$\beta$ -Calcium-Calmodulin-Dependent Kinase II is Associated with Paired Helical Filaments of Alzheimer's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 954-963.	1.8	43
715	Elastase is associated with the neurofibrillary pathology of Alzheimer disease: a putative link between proteolytic imbalance and oxidative stress. <i>Restorative Neurology and Neuroscience</i> , 1996, 9, 213-217.	0.8	8
716	Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. <i>Brain Research</i> , 1996, 717, 99-108.	2.3	63
717	Trypsin interaction with the senile plaques of Alzheimer disease is mediated by $\beta$ -protein precursor. <i>Molecular and Chemical Neuropathology</i> , 1996, 27, 145-154.	1.0	14
718	Oxidative posttranslational modifications in Alzheimer disease. <i>Molecular and Chemical Neuropathology</i> , 1996, 28, 41-48.	1.0	62
719	Amyloidosis, advanced glycation end products and Alzheimer disease. <i>NeuroReport</i> , 1995, 6, 1595.	1.2	25
720	Carbonyl-Related Modification of Neurofilaments in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 434.	1.8	0

#	ARTICLE	IF	CITATIONS
721	Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. <i>Acta Neuropathologica</i> , 1995, 89, 291-295.	7.9	142
722	Non-enzymatically glycosylated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid $\beta$ -peptide. <i>Nature Medicine</i> , 1995, 1, 693-699.	30.1	419
723	Early AGEing and Alzheimer's. <i>Nature</i> , 1995, 374, 316-316.	36.2	69
724	Characterization of the association of phospholipase C- $\beta$ with Alzheimer neurofibrillary tangles. <i>Brain Research</i> , 1995, 669, 217-224.	2.3	20
725	Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease. <i>Brain Research</i> , 1995, 699, 125-129.	2.3	14
726	Radical AGEing in Alzheimer's disease. <i>Trends in Neurosciences</i> , 1995, 18, 172-176.	8.8	471
727	Free radical damage, iron, and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1995, 134, 92-94.	0.6	116
728	Senile plaques and neurofibrillary tangles: The concurrent lesions of Alzheimer's disease. <i>Neurobiology of Aging</i> , 1995, 16, 343-344.	3.2	1
729	Alteration of Phospholipase C- $\beta$ Protein Level and Specific Activity in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1995, 64, 2629-2634.	4.0	26
730	Carbonyl-Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1995, 64, 2660-2666.	4.0	212
731	Induction of Heme Oxygenase-1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1995, 65, 1399-1402.	4.0	199
732	Glial Cell Extracellular Matrix in Alzheimer's Disease. , 1995, , 158-170.		0
733	Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. <i>Brain Research</i> , 1993, 623, 142-146.	2.3	186
734	Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. <i>Brain Research</i> , 1993, 603, 343-347.	2.3	47
735	Chondroitin Sulfate Proteoglycans Are Associated with the Lesions of Alzheimer's Disease. <i>Experimental Neurology</i> , 1993, 121, 149-152.	4.1	165
736	$\beta$ -Amyloid of Alzheimer's Disease Induces Reactive Gliosis That Inhibits Axonal Outgrowth. <i>Experimental Neurology</i> , 1993, 124, 289-298.	4.1	133
737	Abnormal accumulation of phospholipase C- $\beta$ in filamentous inclusions of human neurodegenerative diseases. <i>Neuroscience Letters</i> , 1993, 162, 183-186.	2.1	22
738	Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. <i>Developmental Brain Research</i> , 1993, 72, 41-49.	1.8	42

#	ARTICLE	IF	CITATIONS
739	Î±1-Antitrypsin and Î±1-antichymotrypsin are in the lesions of Alzheimer's disease. <i>NeuroReport</i> , 1992, 3, 201-203.	1.2	123
740	Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. <i>Brain Research</i> , 1992, 579, 350-352.	2.3	41
741	Serial reconstruction of Î²-protein amyloid plaques: relationship to microvessels and size distribution. <i>Brain Research</i> , 1992, 592, 278-282.	2.3	31
742	A Primate Model for Human Cerebral Malaria: <i>Plasmodium coatneyi</i> -Infected Rhesus Monkeys. <i>American Journal of Tropical Medicine and Hygiene</i> , 1992, 46, 391-397.	3.5	69
743	Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. <i>Brain Research</i> , 1991, 558, 43-52.	2.3	15
744	Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease. <i>Brain Research</i> , 1991, 558, 312-314.	2.3	81
745	Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology. <i>Brain Research</i> , 1991, 541, 347-349.	2.3	24
746	Dementia with argyrophilic grains. <i>Annals of Neurology</i> , 1991, 30, 853-853.	5.8	19
747	Role of cytokeratin intermediate filaments in transhepatic transport and canalicular secretion. <i>Hepatology</i> , 1990, 11, 435-448.	8.1	38
748	Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. <i>Brain Research</i> , 1990, 537, 102-108.	2.3	52
749	The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. <i>Annals of Neurology</i> , 1989, 26, 771-778.	5.8	89
750	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. <i>Journal of Neurochemistry</i> , 1989, 52, 1523-1528.	4.0	73
751	The presence of tau distinguishes Lewy bodies of diffuse Lewy body disease from those of idiopathic Parkinson disease. <i>Neuroscience Letters</i> , 1989, 100, 6-10.	2.1	55
752	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1989, 103, 259-262.	2.1	9
753	Soluble derivatives of the Î² amyloid protein precursor of Alzheimer's disease are labeled by antisera to the Î² amyloid protein. <i>Biochemical and Biophysical Research Communications</i> , 1989, 165, 182-188.	2.2	84
754	Immunoaffinity demonstration that paired helical filaments of Alzheimer disease share epitopes with neurofilaments, MAP2 and tau. <i>Brain Research</i> , 1989, 484, 150-156.	2.3	30
755	Influence of neuronal location on antigenic properties of neurofibrillary tangles. <i>Annals of Neurology</i> , 1988, 23, 604-610.	5.8	45
756	Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. <i>Annals of Neurology</i> , 1988, 24, 407-413.	5.8	76

#	ARTICLE	IF	CITATIONS
757	The glucose transporter of the human brain and blood-brain barrier. <i>Annals of Neurology</i> , 1988, 24, 757-764.	5.8	150
758	Paramyosin and actin in schistosomal teguments. <i>Nature</i> , 1988, 333, 76-78.	36.2	138
759	AMYLOID PRECURSOR PROTEIN IN SENILE PLAQUES OF ALZHEIMER DISEASE. <i>Lancet, The</i> , 1988, 332, 746.	12.1	72
760	Arachidonic acid metabolism in <i>Ascidia ceratodes</i> eggs: role of lipid peroxidation. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1988, 90, 785-789.	0.2	1
761	Phosphorylation of Neurofilaments Is Altered in Amyotrophic Lateral Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1988, 47, 642-653.	1.8	186
762	Hirano Body Filaments Contain Actin and Actin-Associated Proteins. <i>Journal of Neuropathology and Experimental Neurology</i> , 1987, 46, 185-199.	1.8	127
763	Hirano bodies contain tau protein. <i>Brain Research</i> , 1987, 403, 337-340.	2.3	92
764	Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. <i>Brain Research</i> , 1987, 420, 233-242.	2.3	28
765	Coexistence of cytokeratin, vimentin and neurofilament protein in human choroid plexus. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1987, 410, 173-177.	1.3	35
766	Microtubules are not altered in the dystrophic chicken. <i>Experimental Cell Research</i> , 1986, 163, 266-272.	2.6	2
767	A STUDY OF ACTIN BINDING PROTEINS IN HIRANO BODIES. <i>Journal of Neuropathology and Experimental Neurology</i> , 1986, 45, 335.	1.8	1
768	Characterization of a Ca <sup>2+</sup> -stimulated lipid peroxidizing system in the sea urchin egg. <i>Developmental Biology</i> , 1985, 107, 47-57.	2.1	37
769	Fertilization stimulates lipid peroxidation in the sea urchin egg. <i>Developmental Biology</i> , 1985, 107, 58-65.	2.1	40
770	Interaction of Calcium-Calmodulin in Microtubule Assembly in Vitro. , 1982, , 73-84.		3
771	Ca <sup>2+</sup> -stimulated production of H <sub>2</sub> O <sub>2</sub> from naphthoquinone oxidation in <i>Arbacia</i> eggs. <i>Experimental Cell Research</i> , 1981, 134, 65-72.	2.6	40
772	Cytochalasin B blocks sperm incorporation but allows activation of the sea urchin egg. <i>Experimental Cell Research</i> , 1980, 126, 333-342.	2.6	38
773	Oxidative Damage and Antioxidant Responses in Alzheimer's Disease. , 0, , 371-378.		2
774	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. , 0, , 341-361.		15

#	ARTICLE	IF	CITATIONS
775	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease. , 0, , 601-607.		0
776	La funci3n del estr3s oxidativo en la patog3nesis de la enfermedad de Alzheimer. Revista Chilena De Neuro-Psiquiatria, 0, 41, .	0.2	0
777	Thinking Outside the Box in Alzheimer Disease Treatment. , 0, , .		0
778	MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?. American Journal of Neuroradiology, 0, , .	2.7	0
779	Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on $\beta$ -Synuclein and Tau Aggregation. ACS Chemical Neuroscience, 0, , .	3.7	0